Phase 1/2, Randomized, Multicenter, Prospective Study of Gemcitabine and Rapamycin (Sirolimus) Combination Versus Gemcitabine Only to Treat Advanced Soft Tissue Sarcoma

Trial Profile

Phase 1/2, Randomized, Multicenter, Prospective Study of Gemcitabine and Rapamycin (Sirolimus) Combination Versus Gemcitabine Only to Treat Advanced Soft Tissue Sarcoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Sirolimus (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Nov 2017 Primary endpoint (Phase 2: Progression Free Survival) has been met as per the results published in the Targeted Oncology
    • 24 Nov 2017 Results published in the Targeted Oncology
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top